Dactolisib

Dactolisib has been studied in 7 papers since 2018: 1 trial in people, 4 in animals, 2 in cells; 1 in the past year. Its furthest trials in people are at phase 3. The newest paper, Oct 13, 2026: “Targeting PI3K/AKT/mTOR Pathway Exerts Inhibitory Effects on Endothelial Cells from Generalized Lymphatic Anomaly”.

InterventionPhase 3

7 papers study it9 findingsUpdated

PubChemChEBIMeSH

1 new paper in 30 daysSee all 7 papers on dactolisib

At a glance

The findings reach people, from one lab or study. 4 independent labs in 4 countries; 7 trials, 1 about aging, 1 with no results posted.

“we found a statistically significant reduction in the proportion of patients who had one or more laboratory-confirmed RTIs in the RTB101 10 mg once daily treatment group”
Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trialsThe lancet. Healthy longevity2021doi:10.1016/s2666-7568(21)00062-3

None of its findings points the other way.

Cells, worms or flies, mice and humans: a single group.
  • 4 independent labs in 4 countries
  • 7 trials, 1 about aging, 1 with no results posted
  • Funders: National Institute on Aging and others
  • 4 of 9 findings with company ties
  • 6 of 7 trials sponsored by its developers
  • Human trial1
  • Animals2
  • Model organisms2
  • Cells2

Studies in people

1 study gave dactolisib to people and measured what changed.

What changedDesignPeopleSource

down: Decreases laboratory-confirmed respiratory tract infectionsOR 0·601 [90% CI 0·391–0·922]

no change: Has no effect on clinically symptomatic respiratory illnessOR 1·07 [95% CI 0·80–1·42]

Randomized trial16 weeks1,500 peopleaged at least 65 yearsAdults aged at least 65 yearsThe lancet. Healthy longevity, May 6, 2021

What did studies of dactolisib find?

7

Studies of dactolisib measured 7 outcomes, among them clinically symptomatic respiratory illness, laboratory-confirmed respiratory tract infections and Endothelial cell functional properties.

Clinically symptomatic respiratory illness

no changein humans1OR 1

1 study
  1. Dactolisib showed no clear effect on clinically symptomatic respiratory illness in humans (OR 1·07 [95% CI 0·80–1·42]).

    “In the full analysis set, RTB101 did not reduce the proportion of patients with clinically symptomatic respiratory illness, the primary endpoint of the trial”

    Human trial16 weeksn = 1,024

    Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials

    The lancet. Healthy longevity

  2. Dactolisib showed no clear effect on clinically symptomatic respiratory illness in humans (phase 3 trial) (26% vs 25%; OR 1·07 (90% CI 0·80-1·42); p=0·65).

    “RTB101 did not reduce the proportion of patients with clinically symptomatic respiratory illness”

    Human trialphase 3 trial10 mg once daily16 weeksn = 1,024

    Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials

    The lancet. Healthy longevity

More on Clinically symptomatic respiratory illness

Laboratory-confirmed respiratory tract infections

downin humans1

1 study
  1. Dactolisib decreases laboratory-confirmed respiratory tract infections in humans (OR 0·601 [90% CI 0·391–0·922]).

    “In this analysis we found a statistically significant reduction in the proportion of patients who had one or more laboratory-confirmed RTIs in the RTB101 10 mg once daily treatment group”

    Human trial10 mg once daily16 weeks

    Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials

    The lancet. Healthy longevity

  2. Dactolisib decreases laboratory-confirmed respiratory tract infections in humans (phase 2b trial, pooled analysis of parts 1 and 2) (19% vs 28%; OR 0·601 (90% CI 0·391-0·922); p=0·02).

    “we found a statistically significant reduction in the proportion of patients who had one or more laboratory-confirmed RTIs in the RTB101 10 mg once daily treatment group”

    Human trialphase 2b trial, pooled analysis of parts 1 and 210 mg once daily16 weeks

    Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials

    The lancet. Healthy longevity

More on Laboratory-confirmed respiratory tract infections

Endothelial cell functional properties

downin human cells1

1 study
  1. Dactolisib decreases endothelial cell functional properties in human cells (GLA-derived endothelial cells from a PIK3CA-mutated sample).

    “Finally, pharmacological treatment reduced GLA-EC functional properties and down-modulated the hyperactivated PI3K downstream substrates.”

    CellsGLA-derived endothelial cells from a PIK3CA-mutated sample

    Targeting PI3K/AKT/mTOR Pathway Exerts Inhibitory Effects on Endothelial Cells from Generalized Lymphatic Anomaly

    Cells

Primordial follicle activation

downin mice1

1 study
  1. Dactolisib decreases primordial follicle activation in mice (slow-frozen ovaries, three weeks after transplantation).

    “showed reduced follicle proliferation and activation compared to both control and rapamycin”

    Animalsslow-frozen ovaries, three weeks after transplantationovarythree weeks post-grafting

    BEZ235-Mediated PI3K/mTOR dual inhibition improves ovarian follicle survival in a preclinical model

    Reproductive biology and endocrinology : RB&E

Akt and mTOR pathway activation

downin mice1

1 study
  1. Dactolisib decreases akt and mTOR pathway activation in mice (chemotherapy-induced (4-HC) activation in organotypic ovarian culture).

    “BEZ235 significantly counteracted chemotherapy-induced activation of both Akt and mTOR pathways”

    Animalschemotherapy-induced (4-HC) activation in organotypic ovarian cultureovary1 μM

    BEZ235-Mediated PI3K/mTOR dual inhibition improves ovarian follicle survival in a preclinical model

    Reproductive biology and endocrinology : RB&E

Lifespan

upin flies1

1 study
  1. Dactolisib extends lifespan in flies.

    “We show that the novel anti-ageing drugs, torin2 and dactolisib (BEZ-235), increase longevity in vivo.”

    Model organisms

    An expedited screening platform for the discovery of anti-ageing compounds in vitro and in vivo

    Genome medicine

Cellular senescence

downin human cells1

1 study
  1. Dactolisib decreases cellular senescence in human cells (primary human cells in culture).

    “The tested drug treatments reduced senescence and other ageing markers”

    Cellsprimary human cells in culture

    A CellAgeClock for expedited discovery of anti-ageing compounds

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

More on Cellular senescence

Has dactolisib been tested in people?

1 of 7 about aging

Yes: 1 trial in people have been published, and 5 trials are registered.

Every condition in trials

  • Respiratory tract infection

    Phase 3Results posted1 trial

  • COVID-19

    Phase 2Active, not recruiting2 trials

  • Hereditary Sensory and Autonomic Neuropathies

    Phase 2Active, not recruiting2 trials

  • Virus disease

    Phase 2Active, not recruiting2 trials

  • Glioblastoma

    Phase 1/2Status unknown1 trial

  • Gliosarcoma

    Phase 1/2Status unknown1 trial

Stopped

Who is developing dactolisib?

1 company: Restorbio.

Companies

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 01 paper in 12 months